What Is PT-141?

PT-141 is a development and research name associated with bremelanotide, a synthetic cyclic peptide investigated within melanocortin-receptor research. The name PT-141 does not by itself identify the complete molecular form, salt or counterion, formulation, concentration, manufacturer, finished product, route, regulatory status, or research material being discussed.

These distinctions form part of the broader identity and evidence framework explained in PT-141 Peptide Research: Identity, Formulation, Evidence, and Regulatory Evaluation. Accurate research coverage should distinguish the peptide substance from a salt form, study preparation, commercial material, compounded preparation, or approved finished product.

Research-use notice: InStrips products are offered for research and analytical use only. They are not intended to diagnose, treat, cure, or prevent any disease, injury, deficiency, absorption disorder, digestive condition, or medical condition.

The presence of the name PT-141 does not establish product identity, purity, sterility, stability, approval, effectiveness, safety, dosage, suitability for personal use, or equivalence to a bremelanotide-containing drug product.

What Does PT-141 Refer To?

PT-141 is a code name that appeared during the research and development history of the peptide later identified formally as bremelanotide.

Depending on the source, PT-141 may refer to:

• the bremelanotide peptide component
• bremelanotide free base
• bremelanotide acetate
• a study-specific formulation
• a laboratory research material
• a commercially labeled peptide product
• a historical development program

These references should not be assumed to describe one identical preparation.

Why Development Codes Are Used

Development codes allow researchers and sponsors to identify a candidate substance or program before a formal nonproprietary or product name is established.

A development code may be used in:

• early laboratory research
• patents
• nonclinical studies
• clinical-study records
• conference materials
• regulatory submissions
• commercial research listings

The meaning of a code may become broader or less precise as it is repeated outside the original development records.

PT-141 and Bremelanotide

FDA review materials describe bremelanotide as previously known as PT-141.

This supports a terminology connection between the names, but it does not mean that every material labeled PT-141 has been shown analytically to be the same molecular form or finished formulation reviewed by FDA.

A label or product listing should not replace confirmation of:

• amino-acid sequence
• molecular mass
• cyclic structure
• salt form
• purity
• concentration
• formulation
• batch identity

What Type of Molecule Is PT-141?

Bremelanotide is described in FDA materials as a synthetic peptide and in chemical databases as an oligopeptide.

It is commonly characterized as a cyclic heptapeptide, meaning that:

• the peptide contains seven amino-acid residues
• the structure contains a covalent ring
• the sequence and stereochemistry are part of its identity
• the cyclic linkage must be characterized

The terms cyclic and heptapeptide describe structural features rather than product quality or research performance.

Why the Cyclic Structure Matters

A cyclic peptide contains a covalent connection that restricts the structure compared with an open linear chain.

Cyclization can influence:

• three-dimensional conformation
• molecular flexibility
• enzyme accessibility
• chromatographic behavior
• solubility
• aggregation
• analytical identification

Cyclic structure does not establish stability under every formulation or experimental condition.

PT-141 Is Not a Complete Chemical Name

The code PT-141 is useful for recognizing the research compound, but it does not state the complete chemical identity.

A fuller description may need to identify:

• amino-acid sequence
• stereochemistry
• terminal groups
• cyclic linkage
• free-base or salt form
• counterion amount
• hydration state
• conjugated or labeled components

These details are important when comparing research materials.

Sequence Identity

Sequence identity describes the order and type of amino-acid residues within the peptide.

Researchers may use:

• mass spectrometry
• tandem mass spectrometry
• amino-acid analysis
• peptide mapping
• chromatographic comparison
• spectroscopic methods

No single abbreviated name substitutes for sequence confirmation.

Stereochemistry

Peptide identity includes the stereochemical form of its amino-acid residues.

A stereochemical difference can affect:

• three-dimensional structure
• enzyme recognition
• chromatographic retention
• receptor-binding assays
• impurity classification

Nominal molecular mass may not reveal every stereochemical difference.

The Ring-Forming Linkage

A cyclic peptide must be characterized not only by residue order but also by the location and chemistry of the ring-forming connection.

Possible analytical questions include:

• which residues form the linkage
• whether cyclization is complete
• whether linear material remains
• whether alternative cyclic forms are present
• whether intermolecular products have formed

The name PT-141 does not communicate these quality attributes.

PT-141 Free Base

PubChem lists bremelanotide and includes PT-141 free base among its synonyms.

The free-base description refers to the peptide component without representing it as a particular counterion salt.

Free-base characterization may include:

• molecular formula
• molecular mass
• purity
• water content
• residual acids
• solid-state form

A commercial material labeled PT-141 may not state clearly whether its reported mass refers to free peptide or a complete salt material.

PT-141 Acetate

PT-141 acetate is a commonly encountered name for bremelanotide associated with acetate as a counterion.

The acetate form may differ from the free peptide in:

• complete molecular formula
• complete molecular mass
• counterion content
• water association
• reported material weight
• pH behavior
• solubility

The acetate designation should be stated rather than omitted when it is known.

PT-141 Acetate and Acetylated PT-141 Are Not the Same Description

Acetate and acetylation refer to different chemical concepts.

PT-141 acetate generally indicates a salt association involving acetate.

An acetylated peptide would contain an acetyl group covalently attached to the peptide at a defined position.

These distinctions affect:

• molecular identity
• mass calculations
• analytical methods
• naming
• comparability

Counterion Content

A peptide salt should be characterized for the identity and amount of the associated counterion.

Relevant measurements may include:

• acetate assay
• molar ratio
• residual trifluoroacetate
• other ionic substances
• water content
• peptide-equivalent content

The word acetate does not establish the exact counterion ratio.

Hydration State

Peptide materials may contain associated water, and separate database records may describe acetate and acetate-hydrate forms.

Water content can influence:

• weighed material mass
• peptide-equivalent calculations
• solid-state behavior
• storage
• reconstitution
• comparability between batches

The hydration state should be distinguished where it affects reported composition.

PT-141 Is Not the Same as a Finished Product

A peptide substance can be incorporated into more than one formulation or research preparation.

A finished product may also include:

• buffers
• tonicity-adjusting substances
• stabilizers
• preservatives
• surfactants
• a delivery device
• a container-closure system

The PT-141 name does not identify any of these product attributes.

Bulk Substance vs Formulated Material

A bulk peptide substance is the active molecular material before it is incorporated into a complete finished preparation.

Bulk-substance testing may focus on:

• identity
• assay
• purity
• related substances
• counterion content
• residual solvents
• water content

Finished-formulation testing includes additional product-specific attributes.

Laboratory Research Materials

A laboratory material labeled PT-141 may be supplied for analytical or experimental work.

Its documentation may or may not specify:

• sequence confirmation
• salt form
• purity method
• counterion content
• water content
• sterility status
• endotoxin status
• batch traceability

The research label alone does not establish a universal quality standard.

Commercial Listings

Online listings may use PT-141 because it is familiar in search language.

A listing may omit:

• formal substance name
• complete molecular form
• manufacturer identity
• batch number
• analytical methods
• full impurity profile
• regulatory status

Commercial repetition of the name is not independent identity confirmation.

Purity Claims

A stated purity percentage should be interpreted according to the analytical method used.

A chromatographic purity result may not identify:

• counterions
• water
• residual solvents
• endotoxins
• all aggregate forms
• inorganic residues
• sequence identity by itself

Purity, identity, total composition, and microbiological quality are separate questions.

Peptide-Related Impurities

Peptide synthesis and storage can produce related substances such as:

• deletion sequences
• truncated sequences
• insertion sequences
• epimerized residues
• oxidized forms
• deamidated forms
• linear or incorrectly cyclized forms
• aggregates

The name PT-141 does not establish which of these have been evaluated.

Manufacturing Method

A synthetic cyclic peptide may be produced through several manufacturing and purification steps.

Variables may include:

• resin and linker selection
• amino-acid coupling
• protecting groups
• cleavage
• cyclization
• purification
• counterion exchange
• drying

Process differences can create different impurity profiles even when the intended peptide is the same.

Formulation Differences

PT-141-related research materials may be presented as:

• dry peptide powder
• lyophilized material
• buffered solution
• concentrated stock
• study-specific injectable formulation
• finished drug product

Evidence involving one format should not be transferred automatically to another.

Reconstitution

A dry research preparation may be combined with a liquid before analytical testing.

Reconstitution variables can affect:

• final concentration
• pH
• ionic strength
• solubility
• aggregation
• surface adsorption
• time-dependent stability

The PT-141 name does not provide a reconstitution procedure.

Concentration Calculations

Reported concentration can depend on whether calculations use:

• free peptide equivalent
• complete acetate-salt mass
• nominal vial content
• assay-corrected peptide content
• water-corrected content
• molar concentration

These calculation bases should not be mixed when research results are compared.

Research Models

PT-141-related research has appeared in several model types.

These may include:

• receptor-binding systems
• cell-based assays
• isolated-tissue studies
• animal models
• human clinical studies involving defined products

Each model answers different questions and has separate limitations.

Melanocortin-Receptor Research

Bremelanotide is discussed within research involving melanocortin receptors.

Experimental work may examine:

• receptor binding
• receptor activation
• concentration-response relationships
• selectivity among receptor subtypes
• cell-signaling measurements
• animal behavioral endpoints

A receptor response does not establish the performance of an undefined commercial preparation.

Mechanism and Product Identity Are Separate

A proposed or measured molecular mechanism concerns how a characterized substance interacts within a defined model.

It does not establish:

• the identity of every PT-141-labeled product
• the purity of a commercial batch
• the formulation of a finished product
• general effectiveness
• general safety
• personal suitability

Mechanistic evidence should remain connected to the material actually studied.

Animal Studies

Animal studies may use study-specific PT-141 or bremelanotide preparations rather than a marketed finished product.

Interpretation may depend on:

• species
• route
• formulation
• experimental amount
• sampling schedule
• behavioral or biochemical endpoint
• assay specificity

Animal findings should not be represented as established human outcomes.

Human Research

Human studies involving bremelanotide use defined protocols and characterized study products.

Study interpretation may require attention to:

• participant population
• product identity
• formulation
• route
• study design
• control group
• outcome definitions
• adverse-event collection

Those findings apply most directly to the product and conditions studied.

PT-141 and Vyleesi

Vyleesi is a proprietary finished drug product containing bremelanotide.

PT-141 is a development or research name associated with the active peptide.

The terms should not be treated as interchangeable because Vyleesi identifies a product with a defined:

• active ingredient
• formulation
• strength
• delivery presentation
• route
• manufacturer
• regulatory status

Approval Is Product Specific

FDA approval applies to the specific product evaluated in the application.

It does not extend automatically to:

• another PT-141-labeled material
• another manufacturer
• another salt form
• another concentration
• another formulation
• a compounded preparation
• a research-only material

A shared active-peptide name does not transfer approval.

PT-141 Is Not a Dosage

The code PT-141 does not specify an amount, concentration, schedule, or injection procedure.

Research-only discussion should distinguish:

• experimental concentration
• test amount
• formulation volume
• sampling time
• study protocol

The name should not be converted into personal-use instructions.

PT-141 Does Not Establish Effectiveness

A development code, peptide identity, receptor interaction, animal result, or product listing does not independently establish effectiveness.

Effectiveness-related conclusions require evidence about:

• the exact product
• the exact population
• the defined outcome
• appropriate controls
• study duration
• reproducibility

The name itself is not an outcome.

PT-141 Does Not Establish Safety

A peptide identity does not establish that every preparation carrying that name has the same safety profile.

Safety-related variables may include:

• molecular form
• impurities
• aggregation
• formulation components
• sterility
• endotoxins
• route
• study duration

Safety findings remain product and evidence specific.

PT-141 Does Not Establish Product Quality

Product quality requires evidence involving defined specifications and methods.

Evaluation may include:

• identity
• assay
• purity
• counterion content
• sterility
• endotoxins
• particulate matter
• stability

The development code alone demonstrates none of these attributes.

How to Read a PT-141 Source

When a source uses the term PT-141, readers should ask:

• Does the source mean bremelanotide?
• Is the free base or acetate form identified?
• Is a finished product named?
• What formulation was used?
• What research model was used?
• Which analytical method confirmed identity?
• What conclusions does the evidence actually support?

These questions prevent the code name from carrying unsupported product meaning.

Relationship to Bremelanotide Terminology

PT-141 and bremelanotide are closely connected names, but the context in which each appears can affect what is being identified.

The terminology relationship is examined directly in PT-141 vs Bremelanotide: Is There a Difference?

Reading FDA Review Materials

The FDA review materials for bremelanotide describe bremelanotide as previously known as PT-141 and place that terminology within a defined regulatory application.

The FDA review concerns a specific regulated product-development record and should not be interpreted as establishing the identity, quality, approval, effectiveness, safety, or suitability of an unrelated material labeled PT-141.

Final Perspective

PT-141 is a development and research name associated with bremelanotide, a synthetic cyclic peptide studied within melanocortin-receptor research.

The name does not identify whether the material is free base, acetate, hydrated salt, bulk substance, laboratory preparation, compounded product, or the approved Vyleesi formulation.

Accurate research-only coverage should identify the complete molecular form, formulation, source, batch, analytical evidence, research model, and regulatory context without presenting PT-141 as proof of product quality, effectiveness, safety, approval, or personal suitability.